Loading cancer entity…
Loading cancer entity…
Clinical trials
75 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT07688356 | Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Jul 8, 2026 |
| clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01472731 | Safety and Imaging Study of GC1008 in Glioma | completed | Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05092802 | The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment | unknown | Phase 2 | 40 | Shanghai Henlius BiotechINDUSTRY | 1 | May 3, 2022 | clinicaltrials |
| NCT02038218 | Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors(DM-CHOC-PEN) | completed | Phase 2 | 29 | DEKK-TEC, Inc.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02898012 | Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status(ATAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | withdrawn | Phase 2 | 0 | Constantinos HadjipanayisOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT01242566 | Temozolomide in Elderly Patients With KPS < 70(TAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 17, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials